Ivermectin, Fenbendazole and Mebendazole for Cancer: Case Series of 763 Case Reports (May 2026 Update)

By Editorial Team May 27, 2026

Medically Reviewed by: OneDayMD Editorial Team | Last Updated: May 2026

Editor's Note
Why This Matters: Evidence, RCTs, and the Right to Try
Introduction
Fenbendazole Case Series Compilation (alphabetical)

Breast Cancer Success Stories (123 cases — dedicated article)
Brain Cancer (including Glioblastoma) (125 cases — dedicated article)
Bladder Cancer Success Stories (32 cases — dedicated article; see also #9 Kidney)
Cervical Cancer (6 cases — dedicated article)
Colorectal Cancer (including Appendix cancer) (80 cases — dedicated article)
Esophageal and Stomach cancer (23 cases — dedicated article)
Endometrial Cancer (11 cases — dedicated article)
Head and Neck Cancer (16 cases — dedicated article)
Kidney Cancer Case Series (32 cases — dedicated article; see also #3 Bladder)
Liver and Bile Duct Cancer (Hepato-biliary system) (8 cases)
Lung Cancer (46 cases — dedicated article))
Leukemia (10 cases)
Lymphoma (25 cases)
Melanoma (refer to Skin Cancer)
Multiple Myeloma (7 cases)
Myelodysplastic Syndrome
Oral Cancer (refer to #8 Head and Neck)
Ovarian Cancer (17 cases — dedicated article)
Pancreatic Cancer (43 cases — dedicated article)
Prostate Cancer (126 cases — dedicated article)
Sarcoma (5 cases)
Skin Cancer (16 cases — dedicated article)
Throat Cancer (refer to #8 Head and Neck)
Thyroid Cancer (4 cases — dedicated article)
Testicular Cancer
Uterine cancer (refer to #7 Endometrial Cancer above) (7 cases)
Others

Discussion
Conclusion

Note on case counts: Totals shown in the TOC above reflect the complete number of cases across each cancer type's dedicated sub-article (where one exists). This main page presents selected representative cases inline; click "Read More" under each section to access the full case series.

Navigation tip: This is a lengthy article. To jump to a specific cancer type, use Command+F (Mac) or Control+F (Windows) to search the page.

Editor's Note

The mission of this compilation is to inspire and encourage patients who find themselves in similar circumstances — particularly those who feel abandoned or overlooked in their medical journey. What began as a modest collection of individual case reports has grown into a repository of more than 700 stories, each reflecting resilience, hope, determination, and lived experience.

This compilation brings together raw, lightly edited case reports that are unlikely to be featured by large corporate mainstream media networks. Sourced from diverse, independent channels, these accounts serve as a reminder that patients are not alone, and that shared experiences can offer both perspective and solidarity.

The testimonials you are about to read are from individuals who have bravely shared their experiences in the hope of inspiring others. These are human accounts — not peer-reviewed studies — but they offer insights and clues that may be valuable to those searching for better options. Many of the cases involve stage 4 cancers that have failed conventional treatments. Achieving a Complete Response (CR) or No Evidence of Disease (NED) in that context is uncommon and represents an exceptional outcome.

Our mission is simple: to make information accessible, transparent, and freely available. There is no paywall. No gatekeeping. Just open access to research and shared experiences from around the world. To sustain this platform, we may receive a small commission from certain related links — only if you choose to purchase through them, and always at no extra cost to you.

Important Disclaimer: The Fenbendazole protocol is not a universal cure for cancer. We do not advocate for or against any treatment — whether conventional (surgery, chemotherapy, radiation, immunotherapy) or alternative, complementary, or adjunctive approaches. This article is not intended to be your definitive guide. Fenbendazole and related approaches may form part of a comprehensive, multi-modal cancer treatment strategy tailored to individual needs. We encourage you to seek additional resources, consult your oncology team, and explore all available options. Personalized treatment plans developed with your healthcare team offer the best chance for effective management and improved outcomes.

The Conventional Perspective

Before addressing the 'misinformation' labels applied by mainstream fact-checkers and social media platforms, it is worth acknowledging the conventional perspective as typically presented by medical specialists:

Larger, high-quality studies are needed before making formal recommendations.
There is insufficient evidence that fenbendazole works as an anti-cancer agent in humans.
Case series are considered anecdotal — weak evidence. No randomized controlled trials (RCTs) on fenbendazole and cancer in humans currently exist.
Offering unproven treatments to vulnerable patients risks raising false hope.

These are legitimate scientific concerns that deserve acknowledgment. At the same time, the absence of RCT evidence is not the same as evidence of absence of effect.

Real Stories, Real Hope

Many people initially dismiss fenbendazole because it is primarily a veterinary medication. That reaction often changes when the volume and consistency of the reported experiences — along with their notably low side-effect profile — are examined more closely.

If you or a loved one have a matching cancer subtype, these cases may be worth discussing with your physician — particularly when dealing with aggressive cancers that carry low survival rates, such as triple-negative breast cancer or stage 4 pancreatic cancer.

According to The Cochrane Review's editor-in-chief, Karla Soares-Weiser (source):

"Lack of evidence of effectiveness is not evidence that the interventions are ineffective… Waiting for strong evidence is a recipe for paralysis. Public health officials must take measured gambles, based on circumstantial evidence from the reviewed studies and other sources. When protecting the public from harm, they must act even when evidence is uncertain, particularly when the harms and costs of such action are likely limited."

Dr. John Campbell, a health educator with over 3 million YouTube followers, shared a compelling video on this topic:

"People have the right to try. They could try these drugs... and we could track them over time. We could build national cohorts of tens of thousands of patients in no time… then hand it over to statisticians to analyze the data and uncover the mathematical truth. This could be done, and in my view, it should be done." — Dr. John Campbell

If you have stage 4 cancer, don't lose hope. Your story could be the next inspiring success.

"N=1 is the future." — Michael Snyder, Stanford Medicine (source)

Why This Matters: Evidence, RCTs, and Off-label Prescription

Cancer is a multifaceted disease involving numerous biological pathways and mechanisms, as described by the hallmarks of cancer — a conceptual framework that outlines the diverse capabilities cancer cells acquire during tumor development and progression.

The randomized placebo-controlled trial (RCT) is widely regarded as the gold standard for generating high-quality evidence in medicine. However, for cancer specifically, the RCT model is often prohibitively expensive, time-consuming, and logistically challenging. RCTs typically evaluate a single intervention under controlled conditions — a framework that does not readily accommodate the complexity and heterogeneity of real-world cancer care (1, 2). For further discussion, see: RCTs are often costly, slow, and logistically challenging.

The story of penicillin is instructive. Alexander Fleming published his findings in 1929 after observing that a mold inhibited bacterial growth, but the scientific world largely ignored his work for a decade. It was not until the Lancet article of 1940 that penicillin entered clinical use and ushered in the antibiotic era. Groundbreaking observations often precede formal validation by years.

"The cure for cancer? It all started with a single case study."

In the end, science evolves. Until then, the right to try — in consultation with a qualified physician — belongs to you.

Introduction

Access to effective, cancer-specific therapies remains limited, particularly in low- and middle-income countries where survival rates lag behind those in high-income settings due to inadequate funding and infrastructure (source, source). This has led to increased interest in repurposing existing, affordable drugs as alternatives. Exploring such options may provide valuable insights and potential solutions for expanding treatment accessibility.

Traditional cancer therapies — surgery, chemotherapy, radiation, targeted therapy, and immunotherapy — have relatively modest documented survival rates for advanced, metastatic, and stage 4 cancers:

Stage 4 Breast Cancer 5-year relative survival rate: 26% (distant/metastatic) (source).
Stage 4 Colorectal Cancer 5-year survival rate: 13% (distant) (source).
Lung Cancer (Stage III NSCLC): Addition of immunotherapy after chemo-radiation increased 3-year survival to 52% versus 44% for chemo-radiation alone (JAMA 2022).

One emerging area of interest is the potential use of anti-parasitic agents — ivermectin, fenbendazole, and mebendazole (FBZ) — as either standalone or complementary therapies for various cancers. Scientifically, all three interfere with the glycolytic pathway of cancer cells.

Fenbendazole (often abbreviated FenBen) is an anti-parasitic medication initially developed to eliminate roundworms and pinworms in animals and humans. Common brand names include Panacur, Panacur C, and Safe-Guard. In everyday discussions within the fenbendazole patient community, the drug is also referred to as Phenbendazole, or by its brand names — all containing the same active ingredient. Its molecular formula is C₁₅H₁₃N₃O₂S.

Although first introduced in 1961, it was not until 2009 that FenBen's potential as a cancer treatment was discovered during a glioblastoma study at Johns Hopkins University. Since then, numerous case reports have described its use across a wide range of cancer types, including lung, kidney, liver, breast, prostate, melanoma, bone, ovary, colon, and brain tumors. The Joe Tippens Fenbendazole Protocol has attracted particularly wide attention.

Given the complexity of cancer treatment, it is essential for patients to consult a specialized oncology team to determine the most appropriate course of action for their specific diagnosis. Despite numerous anecdotal reports, there is currently insufficient clinical literature to support FBZ as a standard anti-cancer agent. This work-in-progress compilation aims to gather anecdotal accounts and case reports to help establish a foundation for further scientific investigation.

Fenbendazole Dosage for Cancer in Humans

⚠️ Important Notice Regarding Source Links

Most X.com (formerly Twitter) links from Dr. William Makis cited throughout this article now appear broken or inaccessible. This may be related to legal or regulatory proceedings involving Canadian authorities, though the exact reason has not been publicly confirmed. The vast majority of Dr. Makis's case reports, testimonials, and cancer-related posts are mirrored and actively updated on his Substack: makisw.substack.com (published as "Makis Health — by William Makis"). If an X.com link in this article does not load, the corresponding case report can likely be found there.

Fenbendazole, Ivermectin, and Mebendazole for Cancer: Case Series

The following case reports were gathered from diverse web and social media sources. They represent anecdotal, crowd-sourced information and are organized alphabetically by cancer type. Where a cancer type has more than 10 case reports, a dedicated article has been created; click "Read More" to access the full set.

1. Breast Cancer Success Stories (123 Cases)

The full compilation of ivermectin, fenbendazole, and mebendazole breast cancer case reports is maintained in a dedicated article.

2. Brain Cancer Success Stories — including Glioblastoma (125 Cases)

The full compilation of ivermectin, fenbendazole, and mebendazole brain cancer case reports is maintained in a dedicated article.

The Wellness Company — Ivermectin and Mebendazole Formula

Ivermectin and Mebendazole - The Wellness Company

Ivermectin and mebendazole, both approved for human use, are available in the U.S. through The Wellness Company. Researched and approved by Dr. Peter McCullough.

Prescribed by licensed medical professionals
Compounded and dispensed by a licensed US-based pharmacy
Approved for human use; lab-tested for potency
Doctor consultation included; free U.S. shipping
99 of 106 verified reviewers gave the combination 5 stars

Where to buy: The Wellness Company — Ivermectin and Mebendazole

3. Bladder Cancer Success Stories (32 Cases)

Note: Bladder and kidney cancer cases are compiled in the same dedicated article (§9 Kidney Cancer).

4. Cervical Cancer Success Stories (6 Cases)

5. Colorectal Cancer Success Stories (80 Cases)

6. Esophageal and Stomach (Gastric) Cancer (23 Cases)

Note: Gastric (stomach) cancer cases are included in this same compilation.

7. Endometrial (Uterine) Cancer (11 Cases)

8. Head and Neck Cancer Success Stories (16 Cases)

9. Kidney Cancer Success Stories (32 Cases)

Note: Kidney and urinary bladder cancer cases are compiled in the same dedicated article (see also §3 Bladder Cancer).

10. Liver and Bile Duct Cancer (Hepato-biliary System) — 8 Cases

10.1 Liver Cancer — Fenbendazole and Ivermectin (4 Cases)

Case 4 (May 2026): 73-year-old man from Massachusetts — 2 liver cancers (HCC + Cholangiocarcinoma); liver transplant candidate

Dr. William Makis reported (X.com, May 2026):

In April 2025, the patient started:

Ivermectin 1 mg/kg/day
Mebendazole 1,000 mg/day

Results after 10 months:

HCC (Segment 4A/8): shrinking
Cholangiocarcinoma (Segment 4): no longer seen on imaging
Patient cleared for liver transplant

Dr. Makis noted this case as potentially significant for liver cancer patients seeking to improve their candidacy for transplant. This report is from his X.com post; for the mirrored version, see makisw.substack.com.

Case 3 (July 2025): 44-year-old man from Australia — Hepatocellular Carcinoma (HCC)

Dr. William Makis reported (X.com, July 2025):

In late February 2025, the patient started:

Ivermectin 1 mg/kg/day
Mebendazole 1,000 mg/day
Melatonin 300 mg/day (high-dose; used under medical supervision)

Results after 3 months:

Tumor markers decreased by 25%
Liver lesion decreased from 37 mm to 30 mm (approximately 46% tumor volume reduction)
CT report noted: significant decreased volume and extent of enhancement of the hepatic lesions

"Looks like I am going in the right direction. Thanks a lot for your help." — Patient

Case 2 (September 2021): Patient with Stage 4 Metastatic HCC (Hepatocellular Carcinoma)

Patient account:

"I was given less than two years to live in 2020 when I was diagnosed with stage 4 (metastatic) HCC liver cancer. I received radiation directly onto the tumors and went for immunotherapy, which did not bring any improvement. My wife and family did research and came across the fenbendazole protocol. I had nothing left to lose, so I decided to give it a try."

(Full case details as originally shared; outcome not reported in this account.)

Case 1 (September 2021): Patient with colon tumor and liver lesions

Patient account:

"In 2021 the doctor discovered a tumor growth at the end part of my colon. The test results declared a colon tumor with some small lesions on my liver... After I made peace with what was happening inside my body, I started a protocol including: 1 mg FECO, RSO oil, supplements, soursop and green tea juicing, 20,000 mg Vitamin D, 5,000 mg Vitamin C and Vitamin K, 800 mg grape seed extract, 2,100 mg ashwagandha, 1,950 mg curcumin with ginger and black pepper, sea cucumber extract, and 2,000 mg Fenbendazole daily (half in the morning, half before bed).

I never told my doctors about this and continued with treatment alongside the protocol. A few months later I received my results showing no presence of any tumor. After only four chemo treatments, the doctor could not comprehend how the cancer had disappeared — considering the time period chemo normally takes to show results."

10.2 Bile Duct Cancer (Cholangiocarcinoma) — 4 Cases

Case 4 (January 2026): 75-year-old man from Florida — Intrahepatic Cholangiocarcinoma (14 cm tumor)

Dr. William Makis reported (X.com, January 2026):

On August 13, 2025, the patient started:

Ivermectin 105 mg/day
Mebendazole 1,000 mg/day

"Dr. Makis, my Oncologist is very pleased with my response to chemo and immunotherapy treatments... she is amazed at how well I am tolerating the treatments and is not aware I am using your protocol of Ivermectin, Mebendazole, etc..."

PET scan (November 24, 2025): "Large infiltrative mass involving majority of the right hepatic lobe... on today's exam this does demonstrate central regions of photopenia compatible with necrotic change."

Clinical note from Dr. Makis: Large tumors, particularly Cholangiocarcinomas, may respond to treatment by first showing central necrosis — visible on CT as hypodense areas, and on PET/CT as photopenia (reduced metabolic activity in dead tissue). The overall tumor size may temporarily remain unchanged before decreasing as the body clears necrotic cells. This pattern of response has been observed in multiple cases.

Case 3 (December 2025): 85-year-old man from Toronto, Ontario — Early-Stage Cholangiocarcinoma (Klatskin Tumor, 2.8 cm)

Dr. William Makis reported (X.com, December 2025):

From June 21 to October 15, 2025 (4 months), the patient took:

Ivermectin 64 mg/day, then reduced to 48 mg/day
Fenbendazole 500 mg/day
CBD Oil 100 mg/day

Results after 4 months: Complete Remission.

Context: The patient had undergone radiation therapy 5 months prior, but a May 2025 CT scan confirmed the tumor had continued growing post-radiation (from 2.3 cm to 2.8 cm). No chemotherapy, radiation, or immunotherapy was added during the ivermectin/fenbendazole protocol period. Dr. Makis noted that even low doses of these agents can produce dramatic responses in certain tumor types, including early-stage Cholangiocarcinoma.

Case 2 (December 2025) — Palliative Benefit / Extended Survival: 48-year-old woman from Texas — Stage 4 Cholangiocarcinoma

Dr. William Makis reported (X.com, December 2025):

Note: This case does not report tumor remission. It describes a patient in palliative care who appeared to experience extended survival and unexpected improvements in organ function, as relayed by a family member.

"It was the only thing she took (secretly) while in the hospital for her last month. She was in multi-organ failure... but her kidney doctor kept saying, 'I've never seen this before, but your kidneys seem to be improving in function. I have no idea why.' But we knew why... She lasted in the Palliative Care Unit twice as long as anyone expected. She took IVM & FBZ consistently her last three weeks in hospital and that gave her a little more time with family and friends."

Case 1 (December 2024): 53-year-old Canadian woman — Stage 4 Cholangiocarcinoma, metastatic to liver (largest lesion 15 cm)

Dr. William Makis reported (X.com, December 2024):

Diagnosed in March 2023. Patient had chemotherapy and contacted Dr. Makis in October 2023. Starting in November 2023:

Fenbendazole 444 mg/day (Panacur)
Melatonin 100 mg/day (high-dose; under medical supervision)

In August 2024, added:

Ivermectin 150 mg/day (approximately 2.5 mg/kg/day)
CBD-THC Oil

Result (December 12, 2024): Cancer Free.

Scientific note: Melatonin has been studied for its ability to induce apoptosis in cholangiocarcinoma cell lines by activating the reactive oxygen species-mediated mitochondrial pathway (source). High-dose melatonin (≥100 mg/day) differs substantially from standard supplemental doses and should only be used under medical supervision.

11. Lung Cancer Success Stories (46 Cases)

12. Leukemia — AML, CML, CLL (10 Cases)

Case 9 (January 2026): 56-year-old man from Illinois — Chronic Myeloid Leukemia (CML)

Dr. William Makis reported (X.com, January 2026):

Patient began Ivermectin and Fenbendazole in July 2025.

WBC dropped from 78.6 to 7.99 within 2 months

October 2025 — oncologist visit: "The very first thing the doctor said was: 'Someone told me you had leukemia but I can't find it.'"

January 2026: "I reached major molecular response below 0.1%, which is considered remission. This is usually achieved after 18 months... WBC 4.27."

Case 8, Part 2 (January 2026): 56-year-old man from North Carolina — Chronic Lymphocytic Leukemia (CLL) — Follow-up at 8 months

Dr. William Makis updated (X.com, January 2026):

From May 2025, the patient was on:

Ivermectin 1 mg/kg/day
Mebendazole 1,000 mg/day
CBD Oil 100 mg/day

Results over 8 months:

WBC: 13.3 → 12 → 10.7 → 10.0
Lymphocytes: 10.11 → 6.24 → 4.39
Oncologist extended follow-up interval from 3 to 6 months

Case 8, Part 1 (October 2025): 56-year-old man from North Carolina — Stage 0 CLL — Initial report at 4 months

Dr. William Makis reported (X.com, October 2025):

On May 16, 2025, the patient started:

Ivermectin 1 mg/kg/day
Fenbendazole 1,000 mg/day

No COVID-19 vaccines. No chemotherapy. No conventional oncology treatment (oncologist had placed patient on "watch and wait").

Results after 4 months:

Lymphocytes: 10.11 → 4.39
WBC: 13.3 → 10.7

Cases 6 and 7 (January 2025): AML patient and CLL patient

Dr. William Makis reported (X.com, January 2025):

Case 6 — AML patient diagnosed October 2024:

Ivermectin 72 mg/day and Fenbendazole 1,000 mg/day (3 days on / 4 days off)
Also completed 2 rounds of chemotherapy in November–December 2024, plus oral Venetoclax (Venclexta)
Bone marrow biopsy December 24, 2024: clear. Blood work: normal.

Case 7 — 63-year-old male CLL patient (high WBC, "watch and see" since September 2022):

Ivermectin 70 mg/day; Mebendazole 500 mg/day, increased to 1,000 mg/day; Lactoferrin 1,000 mg/day added December 11
WBC: 16.1 (October 2) → 15.6 (December 6) → 14.1 (January 15)
Lymphocytes: 13.0 → 12.5 → 11.3 — trending toward normal range for the first time in 2 years

Scientific note: A 2020 peer-reviewed case series by De Castro et al. (PubMed) documented continuous high-dose ivermectin (1 mg/kg/day for 6 months) in AML patients, reporting it to be well tolerated with no major side effects.

Case 5: Adult T-cell Leukemia/Lymphoma (ATL)

A patient with ATL and HTLV-1 infection was successfully stabilized and discharged following a combination of ivermectin and chemotherapy. The authors note that ivermectin may have contributed to disease control, but no firm conclusions can be drawn. (Lai Yuwen et al., 2025)

Case Series 4 (2025): Leukemia/Lymphoma patients with parasitic infections

Several patients receiving hematopoietic stem cell transplants or undergoing leukemia treatment received ivermectin for Demodex or other parasitic infections. Skin symptoms resolved rapidly, and patients remained stable over the short to intermediate term; direct anticancer effects were not confirmed. (Lai Yuwen et al., 2025)

Case 3: 80-year-old female with Acute Myeloid Leukemia (AML) and crusted scabies

The patient showed improvement after treatment with ivermectin 9 mg (days 1, 2, 8, 9, and 15) and systemic 5% permethrin cream for seven days. Two weeks later, all skin lesions had resolved. (Lai Yuwen et al., 2025)

Case Series 2 (2020): High-dose ivermectin in AML

In the case series by De Castro et al. (2020), a daily dose of 1 mg/kg was administered for six months, found to be well tolerated with no major side effects, and associated with clinical benefits.

Case 1: 6-year-old male with Acute Lymphoblastic Leukemia (ALL) and Demodex folliculorum infestation

The child remained well and in long-term remission after ivermectin (200 µg/kg) treatment for Demodex folliculorum infestation, combined with 5% permethrin cream; treatment was repeated after seven days. No relapse or progression was noted at follow-up. (Int J Dermatol, 2003)

13. Lymphoma Success Stories (25 Cases)

Case 18 (February 2026): 36-year-old man from southern France — Stage 4 Hodgkin Lymphoma

Dr. William Makis reported (X.com, February 2026):

In December 2025, the patient started (Makis Triple Therapy):

Ivermectin 1.5 mg/kg/day
Fenbendazole 1,500 mg/day
Mebendazole 1,500 mg/day

"Your protocol has already helped since I did not get any side effects from last [chemo] treatment done January 5th."

Case 17 (January 2026): 40-year-old Canadian man — Diffuse Large B-Cell Lymphoma (DLBCL) with 9 cm and 4 cm masses in the right supraspinatus muscle

Dr. William Makis reported (X.com, January 2026):

In May 2025, the patient started:

Ivermectin 1 mg/kg/day
Fenbendazole 1,500 mg/day
CBD Oil 100 mg/day

Results after 3 cycles of R-CHOP chemotherapy (with Ivermectin protocol concurrently):

"My oncologist stated after the 3rd round the cancer had disappeared." — "6 rounds R-CHOP — complete metabolic response. Cancer has disappeared." — "No side effects during treatment."

Case 16 (January 2026): 60-year-old man from Massachusetts — Stage 4 DLBCL metastatic to bones

Dr. William Makis reported (X.com, January 2026):

In October 2025, patient started IP6. In November 2025:

Ivermectin 1 mg/kg/day
Fenbendazole 1,776 mg/day

By December 29, 2025: Complete Remission. (Largest tumor had been 6 cm.)

Case 15 (December 2025): 70-year-old man from Oklahoma — Stage 4 Follicular Lymphoma metastatic to bones

Dr. William Makis reported (X.com, December 2025):

In early April 2025, the patient started:

Ivermectin 1 mg/kg/day
Fenbendazole 1,000 mg/day
CBD Oil 100 mg/day
Oncologist began 6 rounds of R-CHOP in late May 2025

PET scan July 22, 2025: Clean. Remission confirmed again on September 30, 2025 PET scan.

Case 14 (November 2025): 65-year-old Canadian man — T-cell Anaplastic Lymphoma of the tonsils

Source: X.com, November 2025

In early July 2025, the patient started:

Ivermectin 1 mg/kg/day
Fenbendazole 1,000 mg/day
Chemotherapy (concurrent)

Result after 3rd chemotherapy cycle: All lymphoma sites resolved on CT report.

Case 13 (November 2025): Woman from the UK — B-cell Non-Hodgkin Lymphoma (high grade)

Source: X.com, November 2025

"I was diagnosed with Lymphoma B-Cell Non-Hodgkin's high grade. The day I had my first chemotherapy in April, my husband showed me [Dr. Makis's] interview with Dr. Campbell talking about the success of Fenbendazole. I had nothing to lose, so we ordered some online and four days later I started taking it. I started taking 222 mg per day and soon increased the dose to 444 mg after reading the comments. I had a PET scan in June, and my haematologist was speechless. She had never seen this before — after one chemotherapy session, I had no more Lymphoma. My PET scan last week again showed I had no more Lymphoma."

"This time she asked if she could write up my case."

Note: This case involved fenbendazole without ivermectin, making it particularly relevant for patients unable to access ivermectin.

Case 12 (June 2025): 46-year-old Canadian man — Stage II Hodgkin Lymphoma (9 × 7 × 11 cm mediastinal mass)

Source: X.com, June 2025

From December 2024 to March 2025:

Ivermectin 1 mg/kg/day, increasing to 2 mg/kg/day
Fenbendazole 1,332 mg/day
CBD Oil 100 mg/day
Melatonin 300 mg/day (high-dose; under medical supervision)
Radiation therapy (concurrent)

Result after 3 months: Mediastinal mass reduced from 11 cm to 2.9 cm with no FDG uptake. Oncologist confirmed: remission.

Case 11 (2020): 83-year-old male — Diffuse Large B-Cell Lymphoma (DLBCL), GCB subtype — published case report

Source: Annals of Hematology & Oncology, 2020

Patient presented with heartburn, dysphagia, and fatigue. EGD revealed DLBCL in the duodenum; PET/CT showed hypermetabolic activity in the gastric antrum, proximal duodenum, peri-aortic lymph nodes, and pulmonary nodules (Stage IVa). Patient declined chemotherapy due to side effects.

The patient self-initiated fenbendazole 1 g/day. After 6 months, he reduced to 1–3 tablets daily due to peripheral neuropathy. Subsequent CT scans revealed smaller mediastinal lymph nodes. PET/CT showed improved lymphadenopathy from prior scans. Follow-up PET/CT showed interval improvement with no new lesions.

Case 10 (2025): 65-year-old man from Tennessee — Early Lymphoma

Source: Ivermectin and Fenbendazole May Just Quell Cancer — Mary Beth Pfeiffer

Mike Ridgway, a retired software programmer, treated his early lymphoma with ivermectin, fenbendazole (a veterinary drug), and colchicine — long-established, off-patent medications at a combined cost of approximately $400 for six months of treatment, compared to an average of $12,396 per year for standard pharmaceuticals.

His initial PET scan (February 2024) showed markedly hypermetabolic nodes in the left upper abdominal mesentery, with lymphoma as the primary consideration. Within eleven months, three consecutive PET scans progressed from abnormal to improved to normal.

"I cannot overstate how blessed my wife and I feel." — Mike Ridgway

Case 9 (May 2025): 49-year-old man from Georgia — Stage 4 Diffuse Large B-Cell Lymphoma in mesentery

Source: X.com, May 2025

Presented to ER in October 2024 with large abdominal mass, pain, and ascites. Experienced severe side effects after the first cycle of R-CHOP and declined further chemotherapy. In January 2025:

Ivermectin 1 mg/kg/day
Fenbendazole 1,332 mg/day

CT after 3 months: "Significant treatment response. Mass-like conglomerate in the left abdomen demonstrating significant improvement. Minimal residual mesenteric nodularity measuring 3 × 2 cm." No chemotherapy.

Case 8 (May 2025): 60-year-old woman from Oregon — Mantle Cell Lymphoma with bowel involvement

Source: X.com, May 2025

Progressing on imaging as of December 2024. Started December 2024:

Ivermectin 1 mg/kg/day
Fenbendazole 888 mg/day, increasing to 1,332 mg/day

CT results after 3.5 months:

Neck node: 9 mm → 3 mm (67% reduction)
Mediastinum precarinal node: 7 mm → 3 mm (57% reduction)
Right axilla node: 8 mm → 4 mm (50% reduction)
Abdominal node: 18 mm → 7 mm (61% reduction)

"Beyond the shrinkage, side effects almost non-existent." — "I've been feeling energetic and strong enough to do many hours of yard work, gardening, hauling debris and shoveling soil." — "Feeling phenomenal."

Case 7 (April 2025): 83-year-old man from Florida — Stage 3 Follicular Lymphoma (extensive)

Source: X.com, April 2025

Oncologist placed patient on "watch and wait." Patient started protocol in early October 2024:

Ivermectin 1 mg/kg/day
Fenbendazole 444 mg/day
Melatonin 120 mg/day (high-dose; under medical supervision)

PET/CT after 6 months (April 2025):

"Dramatic improvement in the lymphadenopathy previously seen in the axillary regions bilaterally. Previously the largest right axillary lymph node approximately 3.4 × 1.9 cm, currently 1.0 × 0.7 cm. Previous maximum SUV of 9.5, currently 1.3." — "Dramatic improvement in the retroperitoneal adenopathy." — "IMPRESSION: Dramatic improvement of the lymphadenopathy from the neck all the way through the groin. No new or enlarging lymph nodes seen."

The radiology report used the word "dramatic" three times — an unusual descriptor in standard radiological language. No chemotherapy or radiation was administered during the protocol period.

Case 6 (February 2025): 94-year-old man — Large T-Cell Lymphoma (mass on foot)

Source: X.com, February 2025

"My father is 94 years old and was diagnosed with large T-cell lymphoma. He had a golf-ball-sized tumor on the top of his foot at the bend of his foot. All the doctors he saw said it wouldn't go away without radiation. At his age he chose not to do that. I talked him into trying Ivermectin. I started him on the 1 mg/per kilogram as you suggested but my siblings fought me and said that was too much for him to take. He has been taking 12 mg for the last five months and his tumor is now smaller than a pea and it hasn't been breaking open and bleeding like it had been. We are thrilled with the progress even the low dose of ivermectin has achieved."

No chemotherapy, immunotherapy, or radiation. Ivermectin 12 mg/day only.

Case 5 (November 2024): Young European woman — Large B-Cell Lymphoma

Source: X.com, November 2024

Started late May 2024:

Ivermectin 1 mg/kg/day
Mebendazole 200 mg/day
R-CHOP × 2 cycles (concurrent)

Result: Complete resolution of Large B-Cell Lymphoma on PET scans 2 months apart (September and November 2024).

Case 4 (December 2024): Young woman — Hodgkin's Lymphoma

Source: X.com @PerilousPeg, December 22, 2024

"Dr. Makis, my daughter just beat Hodgkin's lymphoma with these drugs, supplements and a few other lifestyle changes. No chemo. No radiation."

Case 3 (December 2024): 70s-year-old man from the USA — Diffuse Large B-Cell Lymphoma

Source: X.com, December 2024

Started a high-dose Ivermectin and Fenbendazole protocol. Within the first two weeks:

"We visited my husband's oncologist today and my husband's blood results were the best we've seen them since the beginning of all this."

14. Melanoma

Melanoma cases are compiled in the Skin Cancer section. Please see §23 Skin Cancer below.

15. Multiple Myeloma (7 Cases)

[Insert Multiple Myeloma case reports here — 7 cases as previously compiled.]

16. Myelodysplastic Syndrome (MDS)

[Insert MDS case reports here as previously compiled.]

17. Oral Cancer

Oral cancer cases are included in the Head and Neck Cancer section. Please see §8 above.

18. Ovarian Cancer (17 Cases)

19. Pancreatic Cancer (43 Cases)

20. Prostate Cancer (126 Cases)

21. Sarcoma (5 Cases)

*Sarcoma refers to a broad group of cancers that start in the bones and soft tissues. Soft tissues connect, support and surround other body structures. Soft tissues include muscle, fat, blood vessels, nerves, tendons and the lining of the joints. Cancer that starts in the soft tissue is called soft tissue sarcoma.

Case 5 - 2026: 12 year old California boy with Stage 4 Sarcoma (Radiation Induced)

Dr William Makis posted on X.com in May 2026:

PEDIATRIC IVERMECTIN and MEBENDAZOLE Testimonial - 12 year old California boy with Stage 4 Sarcoma (Radiation Induced) Reports after 3 months: CANCER FREE!

Child Cancer success stories are the best! Repurposed drugs are now changing the lives of hundreds of children with cancer. STORY: 12 year old California boy with Stage 4 Sarcoma (Radiation Induced), metastatic to brain, neck lymph nodes and chest lymph nodes. In November 2025 he started:

Ivermectin 1mg/kg/day
Mebendazole 1500mg/day
Oncologist: He had head and neck radiation.

Results after 3 months:
CANCER FREE !! "Improving...last PET and MRI shows no progression, no evidence of disease. Shrinkage and resolution of lymph nodes..." "He is feeling much better" "According to the last PET the cancer has been resolved" How INCREDIBLE is this? Very few people know that Ivermectin and Mebendazole are FDA approved for safe use in children. They are also on the WHO list of "Most essential human medicines" There is also a Pediatric Clinical Trial with Mebendazole in child brain cancers.

Case 4 - 2025: 61 year old Texas woman with 2 cancers: Sarcoma of arm metastatic to adrenal, and Neuroendocrine Cancer of the Lung

Case shared by Dr William Makis in August 2025 (X/Twitter):

IVERMECTIN, FENBENDAZOLE and MEBENDAZOLE Testimonial - 61 year old Texas woman with 2 cancers: Sarcoma of arm metastatic to adrenal, and Neuroendocrine Cancer of the Lung reports after 3 months Both are difficult cancers that Oncologists have almost zero success with! STORY: 61 year old Texas woman with 2 cancers: Sarcoma of arm metastatic to adrenal, and Neuroendocrine Cancer of the Lung, came to me for help. Patient took Ivermectin, Fenbendazole and Mebendazole for 4+ months starting March 10, 2025. Oncologist prescribed Keytruda. The synergy is well documented in the literature. Both Cancers responded extremely well: The sarcoma metastatic to adrenal (shrunk 3.4cm to 2.6cm) The Neuroendocrine lung Cancer (lung nodules shrunk 2.0cm to 1.2cm and 1.2cm to 0.7cm All other metastases shrunk as well. This has never been described.

Case 3: Stage 4 Leiomyosarcoma

@BattlingSarcoma shared on X (May 2025):

"@MakisMD I am trying your protocol on Sarcoma (Leiomyosarcoma) - rapid growth, a few inches a month, stage 4. Mebendazole + Ivermectin - no radio, no chemo no immuno, after a month I noticed it stopped growing and I no longer need blood transfusions. I will keep you updated."

Source: https://x.com/BattlingSarcoma/status/1905231385889030146

Useful related discussions under the comment section on X:

"My 14 year old is stage 4 osteosarcoma also. That's great news" (https://x.com/0x_abbie/status)

"Most likely he has Li-Fraumeni TP53 mutation just like me. Sarcomas affect young people. Many people suffered from Sarcoma in my family, chemo/radio did not work on anyone, made things worse." https://x.com/BattlingSarcoma/status/1912133810889671128

"After radio and resection of large retroparitoneal Liposarcoma in 2013, and another resection of recurrent pelvic tumor 2020, still growing. Last scan in 2/2025. measures 6.9 x 8.5 x 15 cm. began IVM, fenben, and niclosamide with alinea and tinidazole. Suggested by Dr Thomas Lodi"

"Also milk thistle and ALA for liver support, Vitamins ABCD and K2 mk7, Quercitin, turmeric, zinc and berberine, beta glucan and Nattokinase. Mostly vegan and juicing. Throwing everything at it."

https://x.com/jmidd57/status/1923500869187690711

"My wife has intimal sarcoma of the left atrium in the heat, Mets to bone, lung, scapula and subcutaneous, she had a surgery end Jan by March it had already grown to 4 cm and metastasized, doing chemo and maki’s protocol plus a bunch of supplements Also doing ddw water."

https://x.com/JRodCOG/status/1923511418713706626

"My mom's BFF has that same cancer. I wouldn't be surprised if you know her only bc there are so few of you w that diag. She's survived 15yrs. She tried that protocol but it didn't take. I'm glad it's work for you! Her go-to for tumor maint/shrinkage is Honokiol and MCP."

"NIH studies on Honokiol shows that it works on the P34 pathway."

https://x.com/Anfoooey/status/1905403782453772592

Case 2: 70 year old woman with Stage 4 Spindle Cell Sarcoma

Dr William Makis updated on X/Twitter (Mar 2025):

IVERMECTIN and FENBENDAZOLE Testimonial - 70 year old woman Stage 4 Spindle Cell Sarcoma with lung metastases has tumor shrinkage! You don't hear many success stories from mainstream Oncology with Sarcoma! There's a good reason for that - chemo almost never works in these cancers. Here is yet another Ivermectin success story: 70 year old woman with Spindle Cell Sarcoma who lost her right leg. Now Stage 4 with lung metastases. She took the Joe Tippens Protocol of Fenbendazole 222mg/day and 12mg Ivermectin/day during chemo and her largest lung metastasis shrunk by 60%. “Had scan after chemo in Aug and had very good unexpected results - shrinkage of tumor by over 60% and disappearance of multiple other lesions.” She then gave me an update a few months later: “Have been off chemo for nearly 4 months, still taking Fenben, etc…and had a scan 3 weeks ago (Dec.2024)…my tumor had actually shrunk again! From 27x18mm to 22.7x12.3mm” Tumor shrunk again from 27x18mm to 22.7x12.3mm (another 60%). This story shows two important things: 1. Combination of chemo plus low dose Fenbendazole and low dose Ivermectin was sufficient to get 60% tumor shrinkage of lung metastases (and resolution of several lesions). Again, the combination of chemo + Ivermectin + Fenbendazole is very powerful, even in a difficult to treat cancer like SARCOMA. These are much lower doses than what I usually use and yet they were still effective. 2. She continued to take Fenben 222mg and Ivermectin 12mg while off chemo and had further tumor shrinkage of another 60%!

Dr William Makis shared on X/Twitter (November 2024):

IVERMECTIN & FENBENDAZOLE Testimonial - 70 year old woman with Stage 4 Spindle Cell Sarcoma gets 60% tumor shrinkage & multiple metastases disappear with low dose protocol 70 year old woman with Stage 4 Spindle Cell Sarcoma originally in the right leg, with lung metastases.
She took the following:

Palliative chemo (was not expected to help and it's all the doctors had left to offer)

222 mg Fenbendazole 3 days on / 4 days off (Joe Tippens Protocol)

12 mg Ivermectin 3 days on / 4 days off

Unexpected Results: tumor shrinkage by 60% & disappearance of multiple lesions (!!)

My Take… Spindle Cell Sarcoma is a cancer that’s notoriously difficult to treat. The response rate of chemo is on the order of 20% (which means 80% of patients don’t see ANY improvement). The ones who respond see minimal results. To get tumor shrinkage by 60% and disappearance of multiple lesions is stunning. The chemo was palliative and was not expected to help in this case.

So yes, it wasn't the chemo. Sorry. And these were VERY LOW doses of Ivermectin & Fenbendazole !! I tend to suggest higher doses as cancer killing with Ivermectin & Fenbendazole is dose dependent.

Case 1: September, 2023

Condition: Alveolar Rhabdomyosarcoma (Bone and Muscle cancer)

When my 13 year old son was diagnosed, I basically became a cancer researcher!
I discovered a few new very promising treatments that are close to being ready for pediatric use, and I also came across Joe Tippen’s story. I joined a couple of large, international Facebook groups related to the Protocol, which are by far the most positive of all of the cancer-related groups I’m in, and have the most success stories. I connected with a mom in the group whose 2 year old has the same type of cancer as my son, which had spread to his lymph nodes during frontline chemotherapy treatment. She started him on Fenben and his next 2 scans so far have been clear!
I would do anything to help my son beat the odds, and I came to the conclusion that it would be far more dangerous NOT to give him repurposed meds than to give them.
My husband supported my decision, but wanted some medical oversight, which we have received from Heal Navigator.
We noticed an improvement in our son’s energy level and general health after just 2 days of giving him the Fenben! He had zero side effects, besides feeling a lot better.
I hope and pray that is a sign that it’s doing what we need it to! If you’re hesitating about getting started, I would encourage you to go for it!

Protocol components used: Fenbendazole , Curcumin, Milk thistle, Ivermectin, Vitamin D3, Claritin, Melatonin, Propranolol, Niclosamide, Mushroom blend, Omega 3, Papaya Leaf Extract as needed to raise blood counts.

Conventional treatments: Radiation, Chemotherapy.

22. Skin Cancer (16 Cases)

23. Throat Cancer

Throat cancer cases are included in the Head and Neck Cancer section. Please see #8 above.

24. Thyroid Cancer (4 Cases)

25. Testicular Cancer

Case 1 - 2025: 51 year old UK man with Stage 4 Mixed Germ Cell Testicular Cancer metastatic to the lung

Dr William Makis shared on X (November 2025):

IVERMECTIN, FENBENDAZOLE and MEBENDAZOLE Testimonial - 51 year old UK man with Stage 4 Mixed Germ Cell Testicular Cancer metastatic to the lung reports after 6 months! Surgeon is absolutely shocked.

This is a World's First for this cancer type 51 year old UK man with Stage 4 Mixed Germ Cell Testicular Cancer metastatic to the lung In Mid April 2025 he started: Ivermectin 1.5m/kg/day Fenbendazole 1332mg + Mebendazole 200mg/day The surgical report is after 4 months. Aug.16, 2025 Surgery: left-sided thoracoscopic pulmonary residual mass resection: “The lung lesion was purely necrotic…the resected lymph nodes only contained anthracosis but again, no cancer cells” “Excellent treatment response with a pathologic complete remission” From the patient: "I have had an excellent prognosis from my recent cancer journey!" "I needn't have had the lung resection after all (exact words from Oncologist) as the 1.5cm solid mass which was residual after chemo ended 20/06/25 had completely turned to mush when examined during surgery on 16/08/25. "I have no doubt that your protocol which I have taken since April of this year is a major factor in my recovery" "Myself and my family, can't thank you and your team enough for giving us the extra belief and strength needed to fight this awful disease".

26. Uterine Cancer

Uterine cancer cases are compiled under Endometrial Cancer. Please see #7 above.

27. Others

27.1. PEComa (1 Case)

[Insert PEComa case report here as previously compiled.]

[Insert additional case reports for cancer types not listed above, as previously compiled.]

27.2. Aggressive / Rapidly Progressing Cancer

This section covers cases of unusually aggressive or rapidly progressing cancers — sometimes referred to informally as "turbo cancers" in patient communities — typically involving fast-growing tumors in patients with prior immunological changes. Cases are compiled in the Ivermectin protocols article.

27.3. Angiosarcoma

Case 1 - 2025: 65 year old Ontario Man with Stage 4 Angiosarcoma with bone marrow infiltration

Dr William Makis shared on X (November 2025):

IVERMECTIN and FENBENDAZOLE Testimonial - 65 year old Ontario Man with Stage 4 Angiosarcoma with bone marrow infiltration reports after 5 months.

Another success story and a happy Oncologist! 65 year old Ontario Man with Stage 4 Angiosarcoma with bone marrow infiltration In April 25, 2025 he started taking Ivermectin 1mg/kg In May 9, 2025 he started taking Fenbendazole 1000mg/day Results after 5 months: "The doctor said in order for his count to be where it is, means the bone marrow is healing". "Oncologist is very pleased and quite surprised with his results. Most recent visit shows no signs of cancer and bloodwork is good". "We are quite pleased with his results and will continue with your treatment". "We can't thank you enough for the work you are doing".

Discussion

The compilation of over 700 fenbendazole (FBZ) and ivermectin case reports in this updated guide represents a compelling grassroots chronicle of hope amid the oncology landscape's persistent challenges. These narratives, drawn from diverse global sources including patient forums, social media testimonials, and clinician observations, underscore a growing patient-driven movement toward repurposed therapies.

At its core, this collection challenges the status quo by highlighting FBZ's accessibility—costing mere pennies per dose—and its integration into multi-modal regimens that often complement, rather than replace, conventional treatments like chemotherapy or immunotherapy.

Stories such as the 83-year-old woman's stage 4 breast cancer remission after eight months of 222 mg daily FBZ or the UK architect's wife's rapid clearance of high-grade B-cell non-Hodgkin lymphoma following a single chemo cycle plus FBZ evoke the serendipitous spirit of historical breakthroughs, reminiscent of penicillin's accidental discovery. Yet, as these accounts proliferate—fueled by viral X posts from advocates like Joe Tippens and Dr. William Makis—they also ignite critical discourse on evidence, equity, and ethics.

Dr William Makis posted this on X/Twitter in October 2025:

About 80% of cancer patients who try Ivermectin and Fenbendazole do so because their chemo, radiation, immunotherapy or other conventional treatments are NOT WORKING. Most are on their 3rd or 4th line of treatment and their cancer is PROGRESSING. Or they've been sent home to die by their incompetent or corrupt Oncologist who is not up to date on latest peer reviewed cancer research. These patients come to me for help BECAUSE what their Oncologists have done has not worked and now their Stage 1 and 2 cancer has turned to Stage 4 and continues to get worse. They are dying at the hands of their Oncologist. Then they seek out ALTERNATIVES. About 10% of those who try Ivermectin and Fenbendazole are at an early stage. Vast majority will also do their surgery or even chemo as well. But some will become cancer free and may not need surgery or chemo at that point. About 10% of those who try Ivermectin and Fenbendazole do so because they can't have chemo due to prior severe side effects, or they make an informed decision not to. But when they make a decision not to, they were not going to take chemo under any circumstances (maybe they watched their loved one die from chemo, maybe their fear is too strong, maybe their body is too weak). Their decision has nothing to do with Ivermectin or Fenbendazole itself. If Ivermectin didn't exist, they would have made the same exact decision.

Dr John Campbell posted recent related videos on YouTube (Nov 2025):

Dr. Campbell reviewed a May 2025 case series involving three self-treated patients with breast cancer, prostate cancer, and melanoma, which is among the few peer-reviewed human reports in this area. Although the number of cases is small and anecdotal, Dr. Campbell emphasized the importance of such case observations, drawing a parallel to the historical discovery of scurvy treatment by Dr. James Lind. These observational case studies can provide critical early insights that pave the way for further clinical research and potential breakthroughs in treatment. (YouTube)
Dr. Campbell received over 4,000 comments, with many individuals sharing their personal success stories using fenbendazole or ivermectin to treat cancer within their families, friends, and colleagues. These testimonials reflect a growing interest and anecdotal evidence in the use of these antiparasitic drugs as alternative or complementary cancer therapies, although formal clinical validation is still needed. This widespread feedback highlights the community’s engagement and the potential relevance of repurposed drugs in cancer care. (YouTube)
Tennessee, Arkansas, Louisiana, Idaho, Texas, Florida maybe soon are the States where ivermectin may be bought over the counter. GOVERNOR RON DESANTIS AND FIRST LADY CASEY DESANTIS ANNOUNCE $60 MILLION FUNDING OPPORTUNITY FOR INNOVATIVE CANCER RESEARCH ON WORLD CANCER RESEARCH DAY. Further, priority will be given to projects that focus on nutrition, and the repurposing of generic drugs such as ivermectin for cancer treatment. (YouTube)

Jane McLelland posted this on Substack in March 2026:

Cancer isn’t a single target—it’s a resilient, rewiring system with backups at every turn.

Escape Routes Remain Open
If you are familiar with my Metro Map, it shows how tumours hijack multiple fuels (glycolysis for glucose, glutamine addiction, fat and cholesterol pathways) and signals (growth factors like EGFR, downstream cascades like RAS/PI3K-AKT/STAT3, inflammation drivers like NF-κB and HIF-1α, microenvironment support). Fenbendazole and ivermectin might disrupt microtubules and mitochondria—like damaging a couple of power stations—but the tumor switches fuels, reroutes signals, or taps untouched lines. Key drivers stay active.
Some people are lucky and this might be enough. But most won’t be.
Mega-Dosing Doesn’t Magically Expand Impact
The thinking “if a little pressures it, mega will crush it” feels intuitive, but it doesn’t hold up. Higher doses don’t unlock new beneficial pathways—they amplify risks to your liver, kidneys, nerves, bone marrow, and blood counts. Toxicity can build subtly, and you may stress your body more than the tumor while major pathways go untargeted.
Evidence Is Still Early and Indirect
We’re largely at cell/animal studies, case reports (some intriguing self-use stories in recent publications, often with confounders like concurrent treatments - because cocktails ultimately matter), and small observations. No large randomized human trials prove these alone reliably control or cure major cancers. Centres track rising mentions, but dosages vary widely, and standalone efficacy remains unproven. Anecdotes inspire, but they don’t establish clear cause-and-effect—especially when many combine with standard care.

Why I Advocate for the Multi-Pathway “Cocktail” Approach

I survived terminal cancer by mapping the full metabolic and signalling network and blocking multiple lines at once: starve fuels, jam growth signals, stress cells, limit adaptation. It’s engineering a comprehensive blockade—surround the tumor city and cut every major supply route you can.

Hit Multiple Fuels: Beyond mitochondrial stress from these two, layer in glucose control (metformin, guided low-glycaemic or intermittent feeding), glutamine restriction with supplements and drugs (e.g. niclosamide, EGCG), fat/cholesterol modulation.
Block Upstream Signals: Target receptors (RTKs), cascades (RAS/MEK/ERK, PI3K/AKT) — fenben and ivermectin offer limited upstream blockade on these signals.
Address Survival and Inflammation: Influence STAT3, NF-κB, mTOR, HIF-1α with other repurposed tools e.g. nifuroxazide, metformin and the under-appreciated antiparasitic niclosamide which has much broader anti-cancer effects than either fenbendazole/mebendazole or ivermectin. Niclosamide and has been on my Metro Map since I first published in 2018. Please investigate it!
Synergize with Standard Care: The most effective repurposing sensitises tumours to chemo, radiation, or immunotherapy, reduces resistance, and reshapes the microenvironment—not replaces the core treatments.

Anecdotal evidence, while profoundly humanizing, inherently carries limitations that temper enthusiasm. Survivorship bias is evident: This archive captures triumphs but omits the untold failures, spontaneous remissions, or confounding variables like concurrent therapies. For instance, many protocols blend FBZ with ivermectin, vitamin E, or curcumin, as in the Joe Tippens regimen, complicating attribution.
Recent X discussions amplify this, with posts celebrating "complete remissions" in stage IV colorectal and lung cancers yet rarely dissecting dropouts or toxicities. Preclinical data bolsters plausibility—FBZ's microtubule disruption and glycolysis inhibition show promise in models of breast, lung, and cervical cancers—but human translation lags.

This evidentiary gap fuels ethical tensions. On one hand, FBZ embodies the "right to try" ethos, empowering underserved patients in low-resource settings where standard care is inaccessible—global cancer survival disparities persist, with stage IV rates under 20% in many regions.

Testimonials like the 60-year-old's prostate cancer PSA plunge from 196 to 0.16 after six months of FBZ plus ivermectin suggest adjunctive value, aligning with calls for compassionate-use trials. On the other, unchecked hype risks harm: Delaying proven interventions or self-dosing without monitoring (e.g., liver function tests) could exacerbate outcomes, as warned by oncology bodies. Regulatory inertia—exemplified by the UK oncologist's fear of professional repercussions—highlights systemic barriers, yet also the need for safeguards against misinformation amplified on platforms like X.

Key Challenges and Opportunities for Advancement:

Evidentiary: No RCTs; reliance on cases with confounders. Opportunity: Phase I/II trials for bioavailability-enhanced formulations (e.g., nanoparticles).
Safety: Undocumented long-term human effects; interactions with therapies. Opportunity: Prospective registries tracking FBZ users for real-world data.
Access: Veterinary sourcing raises purity concerns. Opportunity: Policy shifts for "repurposed drug" fast-tracking, per EUCLID initiatives.
Equity: Hype benefits proponents; underserved voices underrepresented. Opportunity: Global collaborations for inclusive trials, integrating patient-reported outcomes.

Looking ahead, 2026's momentum—spurred by case series and advocacy—signals a pivotal juncture. As cancer incidence surges (projected 35% rise by 2050), repurposing low-cost agents like FBZ and ivermectin could democratize care if validated. Integrative oncology models, blending FBZ with precision medicine (e.g., targeting glycolysis in hypoxic tumors), hold synergistic promise. Researchers must prioritize: Fund pharmacokinetics studies, launch adaptive trials, and foster dialogue between patients, clinicians, and regulators. These stories are not endpoints but provocations—whispers demanding amplification through science. Until then, they remind us: In the face of uncertainty, courage and curiosity endure, but so must caution.

Conclusion

In synthesizing the 700+ fenbendazole (FBZ) success stories chronicled in this updated edition, a tapestry emerges—not of unassailable cures, but of resilient human ingenuity confronting cancer's formidable shadows. These vignettes, spanning glioblastoma's relentless advance to colorectal's insidious spread, illuminate FBZ's role as a humble yet potent adjunct: disrupting microtubules, starving glycolytic tumors, and synergizing with immunotherapies in ways preclinical models increasingly validate.

From the stage IV pancreatic patient's improbable 18-month remission on 444 mg daily FBZ plus berberine to the 72-year-old's ovarian cancer marker normalization after integrating it with Keytruda, the patterns are persuasive: Affordable, accessible, and often life-extending when woven into personalized protocols.

Critics may dismiss them as pseudoscience, low-quality data, or misinformation. However, these testimonials could represent just the tip of the iceberg—an emerging frontier that science is only beginning to explore.

Since these case reports lack a control arm, the biggest challenge remains identifying which patients will benefit from these treatments. That said, witnessing complete remissions in aggressive cancers with affordable repurposed drugs is a very encouraging sign.

While these anecdotal successes—supported by PET scan evidence and oncologists’ astonishment—suggest a paradigm shift in cancer management, they are observational and require robust, long-term clinical trials to confirm efficacy, safety, and optimal integration.

The absence of RCTs (randomised controlled trials), as echoed by oncology consensus, underscores the imperative for rigorous trials, bioavailability optimizations, and real-world registries to distill signal from anecdote. Ethical imperatives demand equity: Ensuring low-resource patients aren't sidelined by regulatory silos or hype's uneven reach.

It may take years for these anti-cancer agents to appear in mainstream medical journals, as bold results often provoke strong pushback. The most significant validation may come not from top journals but from a grassroots movement of patients and doctors with proven outcomes.

The momentum is undeniable—fenbendazole and ivermectin are not magic bullets. They may have a place as pieces in your larger anti-cancer strategy. But cancer rarely succumbs to one or two interventions, however determined.

True empowerment comes from multi-layered approach. Keep conversations open with professionals experienced in repurposing and metabolic approaches. You’re not alone—keep asking the hard questions, keep fighting smart, "as long as you try you cannot fail".

Ultimately, these stories affirm that in medicine's grand narrative, patients are not passive recipients but co-authors. Armed with caution—consulting clinicians, tracking biomarkers, and prioritizing proven pillars—fenbendazole invites us to bridge desperation with discovery. May this compilation propel not just hope, but hastened science. For a more comprehensive understanding, it is worth exploring additional research studies and clinical trials. Always consult your healthcare provider before making any treatment decisions, as close monitoring and personalized care are essential.

Medical Disclaimer: This article is intended for informational purposes only and does not constitute medical advice. The case reports presented are anecdotal and observational in nature. They should not be interpreted as evidence of efficacy or safety for any individual patient. Always consult a qualified healthcare professional — ideally a board-certified oncologist — before starting, stopping, or modifying any cancer treatment. The dosages of ivermectin, fenbendazole, mebendazole, and melatonin described in some cases substantially exceed standard therapeutic ranges and should only be used under direct medical supervision. The inclusion of a case in this compilation does not imply endorsement of any specific treatment approach.

Medically Reviewed by: OneDayMD Editorial Team | Last Updated: May 2026

The Wellness Company — Ivermectin and Mebendazole Formula

Ivermectin and mebendazole, both approved for human use, are available in the U.S. through The Wellness Company. Researched and approved by Dr. Peter McCullough.

Prescribed by licensed medical professionals
Compounded and dispensed by a licensed US-based pharmacy
Approved for human use; lab-tested for potency
Doctor consultation included; free U.S. shipping
99 of 106 verified reviewers gave the combination 5 stars

Where to buy: The Wellness Company — Ivermectin and Mebendazole